Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
October 12, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
October 05, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
September 28, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
August 11, 2022 08:05 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
May 12, 2022 08:00 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE...
Monopar Announces Clinical and Preclinical Program Updates
February 15, 2022 08:05 ET
|
Monopar Therapeutics Inc.
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15,...
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
June 24, 2021 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
June 03, 2021 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic
May 26, 2021 08:00 ET
|
Monopar Therapeutics Inc.; NorthStar Medical Radioisotopes, LLC
WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional...
Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
May 24, 2021 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional...